专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20100209391A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION 审中-公开
标题翻译： HEPATITIS C VIRUS REPLICATION的新型抑制剂
公开(公告)号：US20100209391A1
公开(公告)日：2010-08-19
申请号：US12769449
申请日：2010-04-28
申请人： SCOTT SEIWERT , LEONID BEIGELMAN , LAWRENCE M. BLATT , TIMOTHY KERCHER , APRIL L. KENNEDY , STEVEN W. ANDREWS
发明人： SCOTT SEIWERT , LEONID BEIGELMAN , LAWRENCE M. BLATT , TIMOTHY KERCHER , APRIL L. KENNEDY , STEVEN W. ANDREWS
IPC分类号： A61K31/404 , C07D403/12 , A61K31/7052 , A61K31/427 , A61K38/21 , A61K31/7072 , A61K31/7068 , A61P1/16
CPC分类号： C07D403/14 , C07D231/56 , C07D471/04
摘要： The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments also provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译：实施方案提供了通式II的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

12. 发明申请

US20100119479A1 THERAPEUTIC ANTIVIRAL PEPTIDES 审中-公开
标题翻译：治疗抗病毒肽
公开(公告)号：US20100119479A1
公开(公告)日：2010-05-13
申请号：US12579275
申请日：2009-10-14
申请人： BRAD BUCKMAN , VLADIMIR SEREBRYANY , SCOTT SEIWERT , LEONID BEIGELMAN , ANTITSA STOYCHEVA
发明人： BRAD BUCKMAN , VLADIMIR SEREBRYANY , SCOTT SEIWERT , LEONID BEIGELMAN , ANTITSA STOYCHEVA
IPC分类号： A61K38/21 , C07D209/12 , C07D401/14 , C07D215/16 , C07D413/14 , A61K31/427 , A61K31/708 , A61K31/52 , A61K31/7076 , A61K31/4035 , A61K31/4439 , A61K31/5355 , A61K31/4709 , A61P31/12
CPC分类号： C07K5/0808 , C07D401/12 , C07D403/12 , C07D417/12 , C07D417/14
摘要： Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, medicaments, and dosage forms related thereto are also disclosed.
摘要翻译：本文公开了由下式表示的化合物：还公开了与之相关的治疗方法，组合物，药物和剂型。

13. 发明申请

US20090131312A1 Non-natural chemokine receptor ligands and methods of use thereof 审中-公开
标题翻译：非天然趋化因子受体配体及其使用方法
公开(公告)号：US20090131312A1
公开(公告)日：2009-05-21
申请号：US11913768
申请日：2006-05-17
申请人： Lawrence Blatt , Scott Seiwert , Hua Tan , Roderick Phillips
发明人： Lawrence Blatt , Scott Seiwert , Hua Tan , Roderick Phillips
IPC分类号： A61K38/16 , C07K14/00 , C12N15/11 , C12N15/00 , A61K31/7088 , C12N5/06 , C12P21/04 , C07K16/18
CPC分类号： C07K14/521 , A61K38/00
摘要： The present invention provides non-natural CXCR3 ligands comprising the N-loop region of the iTAC and polynucleotide encoding such non-natural CXCR3 ligands. The invention additionally provides methods of treating fÊbrotic disorders, angiogenic disorders, and cancer. The methods generally involve administering to an individual in need thereof an effective amount of a non-natural CXCR3 ligand of the invention.
摘要翻译：本发明提供了包含iTAC的N-环区的非天然CXCR3配体和编码这种非天然CXCR3配体的多核苷酸。本发明另外提供了治疗疾病，血管生成障碍和癌症的方法。所述方法通常涉及向有需要的个体施用有效量的本发明的非天然CXCR3配体。

14. 发明申请

US20060269517A1 Use of alpha-glucosidase inhibitors to treat alphavirus infections 失效
公开(公告)号：US20060269517A1
公开(公告)日：2006-11-30
申请号：US11370535
申请日：2006-03-07
申请人： Lawremce Blatt , Hua Tan , Scott Seiwert
发明人： Lawremce Blatt , Hua Tan , Scott Seiwert
IPC分类号： A61K38/21 , A61K31/445 , A61K31/7034
CPC分类号： A61K31/7008 , A61K31/445 , A61K31/7034 , A61K38/21 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.

15. 发明申请

US20060018875A1 Interferon compositions and methods of use thereof 审中-公开
标题翻译：干扰素组合物及其使用方法
公开(公告)号：US20060018875A1
公开(公告)日：2006-01-26
申请号：US11153864
申请日：2005-06-14
申请人： Lawrence Blatt , Ramachandran Radhakrishnan , Scott Seiwert , Hua Tan , Jena Derrick , Jin Hong
发明人： Lawrence Blatt , Ramachandran Radhakrishnan , Scott Seiwert , Hua Tan , Jena Derrick , Jin Hong
IPC分类号： A61K38/21
CPC分类号： A61K38/212 , A61K38/21 , A61K38/217 , A61K2300/00
摘要： The present invention provides compositions, including pharmaceutical compositions, comprising IFN-α and IFN-γ. The present invention further provides methods of treating various disorders, the methods comprising administering an effective amount of a subject composition.
摘要翻译：本发明提供包含IFN-α和IFN-γ的组合物，包括药物组合物。本发明还提供了治疗各种疾病的方法，所述方法包括施用有效量的受试者组合物。

16. 发明申请

US20120101032A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION 审中-公开
标题翻译： HEPATITIS C病毒复制的新型MACROCYCLIC抑制剂
公开(公告)号：US20120101032A1
公开(公告)日：2012-04-26
申请号：US13278984
申请日：2011-10-21
申请人： Brad BUCKMAN , Vladimir SEREBRYANY , John B. NICHOLAS , Scott SEIWERT
发明人： Brad BUCKMAN , Vladimir SEREBRYANY , John B. NICHOLAS , Scott SEIWERT
IPC分类号： A61K38/06 , A61P1/16 , A61P31/14 , C07K5/083 , C12N9/99
CPC分类号： C07K5/0804 , C12N9/99
摘要： The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI and VIa, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译：实施方案提供了通式I，Ia，II，IIa，III，IIIa，IV，IVa，V，Va，VI和VIa的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

17. 发明授权

US07638488B2 Use of alpha-glucosidase inhibitors to treat alphavirus infections 失效
标题翻译：使用α-葡萄糖苷酶抑制剂治疗甲病毒感染
公开(公告)号：US07638488B2
公开(公告)日：2009-12-29
申请号：US11370535
申请日：2006-03-07
申请人： Lawrence M. Blatt , Hua Tan , Scott Seiwert
发明人： Lawrence M. Blatt , Hua Tan , Scott Seiwert
IPC分类号： A61K38/16 , A61K31/70 , A61K31/715 , A61K31/44 , A61K31/445
CPC分类号： A61K31/7008 , A61K31/445 , A61K31/7034 , A61K38/21 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.
摘要翻译：本发明提供了在患有黄病毒感染的个体中治疗黄病毒感染（包括丙型肝炎病毒（HCV）感染）的方法。在一些实施方案中，所述方法包括向有需要的个体施用有效量的抑制膜结合的α-葡糖苷酶抑制剂的酶活性的试剂。在其它实施方案中，所述方法包括向有需要的个体施用有效量的α-葡糖苷酶抑制剂和至少一种另外的治疗剂。

18. 发明申请

US20080019942A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION 失效
标题翻译： HEPATITIS C VIRUS REPLICATION的新型抑制剂
公开(公告)号：US20080019942A1
公开(公告)日：2008-01-24
申请号：US11773912
申请日：2007-07-05
申请人： Scott Seiwert , Leonid Beigelman , Lawrence Blatt , Timothy Kercher , April Kennedy , Steven Andrews
发明人： Scott Seiwert , Leonid Beigelman , Lawrence Blatt , Timothy Kercher , April Kennedy , Steven Andrews
IPC分类号： A61K38/21 , A61K31/4035 , A61K31/416 , A61K31/437 , C07D209/44 , C07D471/04 , C07D231/54 , A61P31/12 , A61K31/505 , A61K31/52
CPC分类号： C07D403/14 , C07D231/56 , C07D471/04
摘要： The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译：实施方案提供了通式I的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案提供了通式II的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案提供了通式III的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

19. 发明申请

US20070117841A1 Use of pirfenidone in therapeutic regimens 失效
标题翻译：吡非尼酮在治疗方案中的应用
公开(公告)号：US20070117841A1
公开(公告)日：2007-05-24
申请号：US10574631
申请日：2004-10-21
申请人： Osman Ozes , Lawrence Blatt , Scott Seiwert
发明人： Osman Ozes , Lawrence Blatt , Scott Seiwert
IPC分类号： A61K31/47
CPC分类号： A61K31/47 , A61K31/4412 , A61K38/212 , A61K38/217 , A61K45/06 , G01N33/5091 , Y02A50/411 , A61K2300/00
摘要： The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment SAPK activity level in a biological sample from the individual with a pre-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step. The present invention provides methods for treating a disorder, and methods for inhibiting a SAPK in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment SAPK activity level in a biological sample from the individual with a first post-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step.
摘要翻译：本发明提供了治疗病症的方法以及在个体细胞中抑制应激活化蛋白激酶（SAPK）的方法，所述方法通常涉及向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物 ; 将来自个体的生物样品中的后处理SAPK活性水平与预处理SAPK活性水平进行比较; 并根据比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。本发明提供了治疗病症的方法以及在个体细胞中抑制SAPK的方法，所述方法通常涉及向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物; 将来自个体的生物样品中的第二后处理SAPK活性水平与第一后处理SAPK活性水平进行比较; 并根据比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。

20. 发明申请

US20070054842A1 Novel macrocyclic inhibitors of hepatitis C virus replication 有权
标题翻译：丙型肝炎病毒复制的新型大环抑制剂
公开(公告)号：US20070054842A1
公开(公告)日：2007-03-08
申请号：US11491126
申请日：2006-07-21
申请人： Lawrence Blatt , Scott Seiwert , Steven Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
发明人： Lawrence Blatt , Scott Seiwert , Steven Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC分类号： A61K38/12
CPC分类号： C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译：实施方案提供通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式